Year: 2025
Type: article
Study design: Observational Study
Abstract: Objective: This study aimed to reveal drug-drug interactions (DDIs) due to antihyperlipidemic drugs through programs used to detect DDIs. Material and Method: 250 prescriptions containing at least one anti-hyperlipidemic drug and a drug from a different pharmacological group were evaluated in terms of DDIs between November 2022 and April 2023. Evaluations were performed using three different DDI checking programs (RxMediaPharma®, Medscape, and Drugs.com) on prescriptions filled by a community pharmacy in Van. Result and Discussion: Anti-hyperlipidemic drug-induced DDIs were detected in 115 of the prescriptions. DDIs occurred between 38 active ingredient pairs. It was determined that 85% of the interactions were caused by atorvastatin. The most common DDI was found between atorvastatin and pantoprazole. For only 7 of the 38 different ingredient pairs, all three programs yielded a result indicating an interaction. DDIs induced by anti-hyperlipidemic drugs were generally found to be at moderate levels. However, it is seen that the three DDI checking programs used in the study provide different results in detecting DDIs.
Authors: Zehra Betül Cengiz, Miray Arslan
Institution: Van Yüzüncü Yıl Üniversitesi
Language: English
Subfield: Geriatrics and Gerontology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7117368896